David Turkaly
Stock Analyst at Citizens
(2.14)
# 2,800
Out of 5,182 analysts
150
Total ratings
38.41%
Success rate
-4.11%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDXG MiMedx Group | Maintains: Market Outperform | $10 → $7 | $3.34 | +109.58% | 2 | Apr 20, 2026 | |
| TELA TELA Bio | Maintains: Market Outperform | $5 → $3 | $0.80 | +275.14% | 8 | Mar 27, 2026 | |
| LNTH Lantheus Holdings | Maintains: Market Outperform | $78 → $85 | $84.11 | +1.06% | 11 | Feb 27, 2026 | |
| AXGN Axogen | Maintains: Market Outperform | $34 → $42 | $39.39 | +6.63% | 9 | Feb 24, 2026 | |
| SYK Stryker | Upgrades: Market Outperform | $440 | $329.01 | +33.73% | 4 | Dec 19, 2025 | |
| APYX Apyx Medical | Upgrades: Market Outperform | $8 | $3.76 | +112.77% | 6 | Nov 12, 2025 | |
| KIDS OrthoPediatrics | Maintains: Market Outperform | $35 → $25 | $15.82 | +58.03% | 12 | Oct 10, 2025 | |
| OFIX Orthofix Medical | Reiterates: Market Perform | n/a | $12.32 | - | 2 | Jun 6, 2025 | |
| GMED Globus Medical | Reiterates: Market Perform | n/a | $93.70 | - | 3 | May 27, 2025 | |
| HAE Haemonetics | Reiterates: Market Outperform | $100 | $60.48 | +65.34% | 12 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $265 → $280 | $222.19 | +26.02% | 18 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $35 → $25 | $10.69 | +133.86% | 15 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $62 → $55 | $24.54 | +124.12% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $140 → $125 | $92.59 | +35.00% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $400 → $500 | $454.61 | +9.98% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $135.07 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $13.15 | +143.35% | 7 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $16 | $6.06 | +164.03% | 1 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $3 | $1.69 | +77.51% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $9.44 | -47.03% | 1 | Oct 6, 2017 |
MiMedx Group
Apr 20, 2026
Maintains: Market Outperform
Price Target: $10 → $7
Current: $3.34
Upside: +109.58%
TELA Bio
Mar 27, 2026
Maintains: Market Outperform
Price Target: $5 → $3
Current: $0.80
Upside: +275.14%
Lantheus Holdings
Feb 27, 2026
Maintains: Market Outperform
Price Target: $78 → $85
Current: $84.11
Upside: +1.06%
Axogen
Feb 24, 2026
Maintains: Market Outperform
Price Target: $34 → $42
Current: $39.39
Upside: +6.63%
Stryker
Dec 19, 2025
Upgrades: Market Outperform
Price Target: $440
Current: $329.01
Upside: +33.73%
Apyx Medical
Nov 12, 2025
Upgrades: Market Outperform
Price Target: $8
Current: $3.76
Upside: +112.77%
OrthoPediatrics
Oct 10, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $15.82
Upside: +58.03%
Orthofix Medical
Jun 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $12.32
Upside: -
Globus Medical
May 27, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $93.70
Upside: -
Haemonetics
May 20, 2025
Reiterates: Market Outperform
Price Target: $100
Current: $60.48
Upside: +65.34%
May 16, 2025
Maintains: Market Outperform
Price Target: $265 → $280
Current: $222.19
Upside: +26.02%
May 9, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $10.69
Upside: +133.86%
May 9, 2025
Maintains: Market Outperform
Price Target: $62 → $55
Current: $24.54
Upside: +124.12%
May 7, 2025
Maintains: Market Outperform
Price Target: $140 → $125
Current: $92.59
Upside: +35.00%
May 5, 2025
Maintains: Market Outperform
Price Target: $400 → $500
Current: $454.61
Upside: +9.98%
Apr 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $135.07
Upside: -
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $13.15
Upside: +143.35%
Jan 29, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $6.06
Upside: +164.03%
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $1.69
Upside: +77.51%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $9.44
Upside: -47.03%